Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 9 (1), 33-39
- https://doi.org/10.7150/ijms.9.33
Abstract
Objective: The safety profiles of oral fluoropyrimidines were compared with 5-fluorouracil (5-FU) using adverse event reports (AERs) submitted to the Adverse Event Reporting System, AERS, of the US Food and Drug Administration (FDA).Keywords
This publication has 37 references indexed in Scilit:
- Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting SystemPLOS ONE, 2011
- Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERSJournal of Experimental & Clinical Cancer Research, 2011
- Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursementBMC Cancer, 2011
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsBritish Journal of Cancer, 2011
- Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trialAnnals Of Oncology, 2009
- Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trialBMC Cancer, 2009
- Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and futureExpert Review of Anticancer Therapy, 2007
- Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancerEuropean Journal of Cancer, 2006
- A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnnals of Oncology, 2005
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEuropean Journal of Cancer, 2002